Guidance

Clinical guidelines for immunoglobulin use (second edition update)

皇冠体育app Clinical Guidelines for Immunoglobulin Use, implemented in 2008, are to ensure best practice in the use of immunoglobulin across all indications.

Documents

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

皇冠体育app guidelines were developed utilising an evidence review and extensive consultations with clinicians and other stakeholders. This Update fulfils the commitment made in the Second Edition to undertake a biennial review from 2009. 皇冠体育app Second Edition Guidelines remain in place, and this Update should be used in conjunction with them.

皇冠体育app Clinical Guidelines support the DH-initiated National Demand Management Programme for Immunoglobulin to provide guidance on appropriate use, to manage demand and to ensure supply for patients for whom immunoglobulin is life-saving.

Arrangements for future immunoglobulin guideline reviews, in the context of the changes in the wider NHS, are currently under discussion. We will give notification of future arrangements in due course.

Updates to this page

Published 23 August 2011

Sign up for emails or print this page